The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The Russian government plans to speed up the development and production of domestic drugs against rare diseases amid the ever tightening pressure caused by sanctions on the country due to its military conflict with Ukraine. 6 October 2022
In the USA, Eli Lilly and Teva Pharmaceutical will meet in court after a federal judge slapped down an attempt to invalidate three of the latter’s patents. 6 October 2022
The PERLA Phase II trial of cancer drug Jemperli (dostarlimab) met its primary endpoint of objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined by blinded independent central review, says UK pharma major GSK, which is a late comer to the PD-/PD-Li inhibitors sector. 6 October 2022
Glenmark Pharmaceuticals’ shares rose 1.2% to 408.75 rupees today, after the Indian drugmaker announced that it became the first company in India to launch thiazolidinedione lobeglitazone for the treatment of type 2 diabetes in adults. 6 October 2022
Market authorization was granted to 92 new medicines in the European Union (EU) last year.Market authorization was granted to 92 new medicines in the European Union (EU) last year. 5 October 2022
Victor Grifols Roura, who has devoted 50 years to building Spanish plasma-derived drugmaker Grifols (MCE: GRF) in senior roles including chief executive for 30 years, retires as non-executive chairperson. He is designated as chairperson of honor in recognition of his numerous contributions. 5 October 2022
Allecra Therapeutics, a France-based biopharmaceutical company dedicated to the development of novel antibiotics, today revealed that the prestigious Journal of the American Medical Association (JAMA) has published the final results from its Phase III ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract infections (cUTIs). 5 October 2022
The ability of patent holders to preserve their market exclusivity, a lack of consumer understanding and other factors have held up the widespread adoption of biosimilars in the USA compared to other markets. 5 October 2022
The US Government has expressed a vote of confidence in Vir Biotechnology, awarding the company a multi-year contract to advance the development of a full portfolio of innovative medicines. 5 October 2022
US pharma giant Pfizer has presented promising results on its PARP inhibitor Talzenna (talazoparib) alongside Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC). 5 October 2022
Cash rich Pfizer has completed its $11.6 billion acquisition of Biohaven Pharmaceutical, including its money-making calcitonin gene-related peptide (CGRP) programs. 5 October 2022
Japanese biotech Kyowa Kirin today announced it has launched its corporate venture capital (CVC) fund and invested in its first biotech start-up. 5 October 2022
Shares of Japanese drugmaker Astellas Pharma rose 2.2% to 1,965 yen yesterday, after it announced a research deal with Germany’s Pantherna Therapeutics, which aims to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation). 5 October 2022
Japan’s largest drugmaker Takeda says that it will discontinue manufacturing its injectable parathyroid hormone Natpar/Natpara globally at the end of 2024 due to unresolved supply issues that are specific to the product. 5 October 2022
Privately-held US biotech company ImaginAb has had what it has describes as ‘a transformational year’ in an update on its achievements over the year. 4 October 2022
French pharma major Sanofi has entered into a collaboration and licensing agreement with little known US biotech miRecule, an innovator of next-generation RNA therapeutics. 4 October 2022
The US Department of Health and Human Services (HHS) said yesterday that it is implementing Medicare Part B payment changes for certain biosimilars, one of the first Medicare provisions of the Inflation Reduction Act to go into effect. 4 October 2022